We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Consort Medical Plc | LSE:CSRT | London | Ordinary Share | GB0000946276 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,010.00 | 1,005.00 | 1,010.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/2/2019 21:22 | I see that RX Securities( of whom I have never heard but specialize in life science companies) have put out a note on CSRT following the Mylan announcement yesterday in which they maintain their buy recommendation and fair value of 1230p | cerrito | |
31/1/2019 12:56 | This should move the share price. in the uk the generics are selling well. when launched in the us should produce large volume orders . if first generic to market ..... | haroldthegreat | |
07/12/2018 11:36 | Rather perplexed about fall in price yesterday and perhaps Oppenheimer continuing to sell but their sale on the 4th should not have such an impact on the price. I see current price lower than that of its predecessor BPK where I made my initial purchase in May 2007 at 749p | cerrito | |
04/12/2018 09:22 | I agree with you jurgenklopp and I have topped up. I have been toying with buying given the recent price weakness and just as well decided to wait till the interims. I have a lot of time for management but have yet to work out how will be impacted by Brexit. | cerrito | |
04/12/2018 08:45 | Interims out today A £3 million hit on this years results for the following reason: "Due to the delay with Mylan in their Wixela(R) (generic Advair(R)) programme, the Board expects profit before tax for the current financial year to be adversely impacted by approximately GBP3m as compared to their previous forecast. Whilst the delay in approval of this programme and near-term anticipated negative impact on our business is disappointing, our view of the peak sales opportunity for the product remains unchanged." Shares down 20% at the moment. Looks like an overreaction. | jurgenklopp | |
14/9/2018 13:07 | Another small pharma company SBTX is gonna have his human trials next week or so! | costax1654x | |
08/6/2018 15:48 | What's going on here? Huge ups and downs, predominantly ups. It is a possible takeover by someone in America? | judyelliot | |
10/12/2017 11:37 | Have not had time yet to have a detailed look at the interims. I see the FT weekend carried a IC buy recommendation due to novel range of auto injectors expected to launch in 2020. Says Investec-house broker-forecasting pre tax profits and EPS for year to 4/2018 of £35.8m and 60.9p going to £40.3m and 66.8p in following year. I do not see the share price doing very much either up or down. | cerrito | |
29/11/2017 13:01 | Cerrito Any ideas on the current rise? | martini | |
12/10/2017 18:20 | Cerrito Yes. I am still hanging in. | martini | |
11/10/2017 13:09 | A testament to the solidity of the CSRT shareholder base was that today's RNS with news of a 1%+ increase in the holding of Neptune was the first change in holdings RNS since January this year. | cerrito | |
16/6/2017 20:20 | The Market seems to like the results. | martini | |
15/6/2017 10:57 | Had a quick read through of the results and small fall in share price seems about right. Was hoping for a sales increase of more than 2% in constant currency and an ebit increase of more than 4.1% but as they say this is a long lead time business. Note that 60% of their sales in Europe and less than 10% in the UK and no mention of Brexit-I guess it will make an appearance in the Risks section of the AR. or various reasons I have lightened up in the last months but a happy with what I have and I guess they will as normal have had a webcast this morning and I will need to go through that. | cerrito | |
23/2/2017 16:19 | taken a small position on the break of the recent down trend. woody | woodcutter | |
04/1/2017 20:26 | I suppose yesterday’s share price fall was to be expected following the news on Voke/Dev200 but have to say that not really surprised by it especially given that BAT have been so tight mouthed. Furthermore BAT in their last interim and full year statement had waxed lyrical on NGP(Next Generation Product) but poor old Nicoventures never got mention. Glenn was asked about it in the interims webcast and stonewalled and referred people to BAT. That said I see that Edison following yesterday’s news have lowered their valuation range from 1459p/1421p to 1238p/1300p. On the full corporate front,Glenn seemed happy enough with what is going on in the webcast and echoed the positive comments in the Outlook Statement. Given the amount of business they do in Europe no mention in the webcast on Brexit-nor in the interims and I see in the last AR not classified as a significant risk. | cerrito | |
07/9/2016 20:01 | Cerrito Surely if you are a big exporter then more pounds for your Euro at present. Even if we end up out of the single Market and get hit with say a 5% import tax into the EU then the current 10% drop in the £ value would more than cover it. At present and for the next 2-3 years it is a windfall, net of course of any hike import raw material rises. | martini | |
07/9/2016 19:32 | Martini, as per Aesop's fable the tortoise can and does beat the hare. I did not make the AGM and would be interested to hear from anyone who did- I have quite a lot in this company-at least by my standards- and one reason for me not going was that I get(or at least I like to think I get) a good feel from the 2 analysts webcasts they have pa and the analysts ask on the whole good questions. I was very interested in how relaxed they are ref Brexit given their heavy European involvement. | cerrito | |
07/9/2016 18:01 | The Market likes it. What am I doing in this "sensible" share? | martini | |
29/7/2016 20:21 | hxxp://www.consumere | martini | |
20/7/2016 11:25 | Just listened to the webcast of the prelims. For those who will be listening need to be patient as they have about 10 minutes of music at the start. Upbeat presentation and good q and a. interesting this was held a week before the referendum and despite 2/3rds of sales in Europe ex UK no one asked about effects of referendum. An obvious question if I make the AGM Another thing I did not get a clear handle on is how much inventory risk they have but was pleased to see year end inventories were £30m against H2 sales of £276m so quick turnover. A good deal of discussion on dev 610 and fact that built a factory bigger than the Nicoventures one for that but I was not sure who has the risk if the orders are not there…especial Good to see positive comment on Voke. Continue to be comfortable with my holding and do not see myself as buying or selling. | cerrito | |
16/6/2016 13:24 | Thanks for that aim_master Need to have a good look at the figures; I do see that 60%+ sales are in Europe so I went to see if they had a Risks section in these prelims to see what if anything they say on the referendum but they did not have this section(nothing unusual about that) so will need to wait till the annual report. | cerrito |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions